Abstract
Introduction:
Transgender and gender-diverse (TGD) individuals represent a growing yet underrepresented group in medical literature. Estrogen and antiandrogens are essential in feminizing gender-affirming hormone therapy (f-GAHT) for individuals assigned male at birth (AMAB). This study examines f-GAHT effects on de novo nephrolithiasis risk in TGD individuals AMAB.
Methods:
This big data study utilizes medical records from the National Institutes of Health’s All of Us database. The cohort includes patients AMAB who self-identified as non-binary, female, transgender women or had a relevant gender diagnosis. The cohort was divided into f-GAHT and non-f-GAHT groups. Cumulative incidence was calculated for each group. Participants were subdivided into estrogen-only f-GAHT (e-f-GAHT) and combined estrogen and antiandrogen f-GAHT (c-f-GAHT) groups. Univariate, unweighted multivariate, and weighted propensity score multivariate analyses were used to explore the association between nephrolithiasis and GAHT.
Results:
A total of 777 patients AMAB met our inclusion and exclusion criteria. The cumulative incidences of kidney stones were 10.3% and 4.8% in the f-GAHT and non-f-GAHT groups, respectively (p = 0.01). Kidney stone odds were 2.53 and 2.76 times greater in the unweighted and weighted regressions for f-GAHT compared with non-f-GAHT patients (p = 0.044 and p < 0.001, respectively). C-f-GAHT was associated with kidney stones in a weighted model (odds ratio [OR]: 2.63, 95% confidence interval [CI]: 1.44, 4.97, p = 0.002), whereas e-f-GAHT was not (OR = 1.88, 95% CI: 0.85, 4.32, p = 0.13).
Conclusions:
We observed a greater de novo incidence of nephrolithiasis among patients on f-GAHT. Antiandrogen therapy may work synergistically with estrogen to increase nephrolithiasis risk. Patients AMAB should be counseled about increased risk when starting f-GAHT, particularly if antiandrogens are included.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
